Corporate Profile
HCW Biologics Inc. (Nasdaq: HCWB) is a clinical stage biopharmaceutical company developing first-in-class immunotherapies to revolutionize the treatments for autoimmune diseases, cancer and senescence-associated dysplasia.
We have created novel fusion compounds that represent a new class of drugs that we believe have the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. Among other things, we have begun commercialization of certain commercial-ready proprietary compounds for use as reagents in the production of immunotherapeutics for the treatment of infectious diseases and cancer. We hope our products improve patients’ healthspan as well as their quality of life, and possibly extend longevity.
HCW Biologics Inc.(NasdaqGM:HCWB) added to S&P TMI Index
Corporate Presentation
Minimum 15 minutes delayed. Source: LSEG
News Releases
Apr 27, 2026
Mar 31, 2026
Mar 17, 2026
Mar 16, 2026
Events
SEC Filings
| Filing date | Description | Form |
|---|---|---|
| Amended Registration statement for face-amount certificate companies | S-1/A | |
| Registration statement for face-amount certificate companies | S-1 | |
| A preliminary proxy statement providing notification matters to be brought to a vote | PRE 14A | |
| Report of unscheduled material events or corporate event | 8-K | |
| Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy | DRS | |
| Report of unscheduled material events or corporate event | 8-K | |
| Annual report which provides a comprehensive overview of the company for the past year | 10-K |